Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma

Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study

(2019) Antonella Argentiero et al.   Cancers

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients

(2018) Patrizia Leone et al.   OncoImmunology

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma

(2016) Yuri Cho et al.   DIGESTIVE DISEASES AND SCIENCES

Hepatocellular carcinoma

(2016) Josep M. Llovet et al.   Nature Reviews Disease Primers

Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?

(2015) Antonio Gnoni et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Making sorafenib irresistible:In vivoscreening for mechanisms of therapy resistance in hepatocellular carcinoma hits on Mapk14

(2015) Matias Avila et al.   HEPATOLOGY

Activated hepatic stellate cells promote angiogenesis via interleukin-8 in hepatocellular carcinoma

(2015) Bing Zhu et al.   Journal of Translational Medicine

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

(2015) Kornelius Schulze et al.   NATURE GENETICS

Up-regulation of REG3A in colorectal cancer cells confers proliferation and correlates with colorectal cancer risk

(2015) Ying Ye et al.   Oncotarget

Intratumor Heterogeneity in Hepatocellular Carcinoma

(2014) J. Friemel et al.   CLINICAL CANCER RESEARCH

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

(2013) Philip J. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

(2013) Ann-Lii Cheng et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma

(2013) Ghassan K. Abou-Alfa et al.   JOURNAL OF HEPATOLOGY

PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation

(2011) Roberto Gedaly et al.   JOURNAL OF SURGICAL RESEARCH

Update on the pathophysiology of liver fibrosis

(2010) Massimo Pinzani et al.   Expert Review of Gastroenterology & Hepatology

Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma

(2008) D. Y. Chiang et al.   CANCER RESEARCH